Drug Profile
Research programme: quassinoid therapeutics - Tapestry Pharmaceuticals
Alternative Names: NBT-273; TPI-273Latest Information Update: 19 Nov 2007
Price :
$50
*
At a glance
- Originator Tapestry Pharmaceuticals
- Class Quassins
- Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer